SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
SEC Accession No. 0001140361-24-037423
Filing Date
2024-08-15
Accepted
2024-08-15 06:52:59
Documents
5
Period of Report
2024-08-15

Document Format Files

Seq Description Document Type Size
1 PREM14A ny20030749x7_prem14a.htm PREM14A 3604278
2 FILING FEES TABLE ny20030749x7_ex107.htm EX-FILING FEES 10487
3 logo_seres.jpg GRAPHIC 51341
4 ny20030749x7_pc01.jpg GRAPHIC 631326
5 ny20030749x7_pc02.jpg GRAPHIC 573371
  Complete submission text file 0001140361-24-037423.txt   5344848
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREM14A | Act: 34 | File No.: 001-37465 | Film No.: 241210573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)